Abstract
Inclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA (siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby decreasing circulating low-density lipoprotein cholesterol (LDL-C). In the EU, inclisiran is indicated in adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet. It is intended for use in patients unable to reach LDL-C goals on maximally tolerated statin therapy, with or without other lipid-lowering therapies (LLTs). In patients who are statin intolerant or for whom a statin is contraindicated, it can be used with or without other LLTs. In clinical trials, twice-yearly injections of inclisiran (after initial doses at days 1 and 90) approximately halved LDL-C levels in patients with, or at high risk of developing, atherosclerotic cardiovascular disease (ASCVD) who had hypercholesterolemia, irrespective of whether or not their existing treatment included a statin. The safety and tolerability profile of the drug was similar to placebo, although mild to moderate, transient injection-site adverse reactions were more frequent with inclisiran. Pending confirmation of the expected reduction in cardiovascular (CV) events with inclisiran, it is a valuable additional/alternative antihyperlipidemic agent to a statin, as its infrequent maintenance dosing regimen confers a convenience advantage over other non-statin LLTs.
Plain Language Summary
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death and disability. ‘Statins’ are the drugs of choice for reducing elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with, or at risk of developing, ASCVD. However, due to multiple factors, including adverse events and/or poor adherence, many patients don’t achieve their guideline target LDL-C level on conventional (statin-based) therapy and novel, non-statin lipid-lowering therapies (LLTs) are needed. Inclisiran (Leqvio®) is a small interfering RNA (siRNA) drug that works as an LLT by stopping the liver from making an enzyme [proprotein convertase subtilisin/kexin type 9 (PCSK9)] that otherwise reduces its ability to remove LDL-C from the blood. Subcutaneously injecting inclisiran every 6 months (after initial doses at days 1 and 90) was generally well tolerated and approximately halved LDL-C levels in patients with, or at high risk of developing, ASCVD who had hypercholesterolemia, regardless of whether or not their conventional therapy included a statin. Inclisiran is a potentially valuable additional/alternative antihyperlipidemic agent to a statin because of its infrequent, and therefore more convenient, dosing schedule versus other non-statin LLTs, including anti-PCSK9 monoclonal antibodies.
Similar content being viewed by others
References
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139:e1082–143.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardio-vascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–88.
Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56.
Catapano AL, Tokgözoğlu L, Mello A, et al. Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. Atherosclerosis. 2019;39(Suppl):100002.
Fox KM, Tai MH, Kostev K, et al. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate intensity statins. Clin Res Cardiol. 2018;107(5):380–8.
Marz W, Dippel FW, Theobald K, et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018;268:99–107.
Cannon CP, Khan I, Klimchak AC, et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:959–66.
Bruckert E, Parhofer KG, Gonzalez-Juanatey JR, et al. Proportion of high-risk/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review. Adv Ther. 2020;37:1724–36.
Hardy J, Niman S, Pereira E, et al. A critical review of the efficacy and safety of inclisiran. Am J Cardiovasc Drugs. 2021;21(16):629–42.
Halava H, Huupponen R, Pentti J, et al. Predictors of first-year statin medication discontinuation: a cohort study. J Clin Lipidol. 2016;10(4):987–95.
Bardolia C, Amin NS, Turgeon J. Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol. Front Cardiovasc Med. 2021;8:789931.
Coppinger C, Movahed MR, Azemawah V, et al. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022;27:1–14.
Catapano AL, Pirillo A, Norata GD. New pharmacological approaches to target PCSK9. Curr Atheroscler Rep. 2020;22:24.
German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020;34(1):1–9.
Macchi C, Ferri N, Sirtori CR, et al. Proprotein convertase subtilisin/kexin type 9: a view beyond the canonical cholesterol-lowering impact. Am J Pathol. 2021;191(8):1385–97.
Dyrbus KM, Gasior MM, Penson PM, et al. Inclisiran: new hope in the management of lipid disorders? J Clin Lipidol. 2020;14:16–27.
Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389–95.
Novartis Europharm Limited. Leqvio 284 mg solution for injection in pre-filled syringe: EU prescribing information. 2021. https://www.ema.europa.eu. Accessed 24 Jan 2023.
Novartis Pharmaceuticals Corporation. LEQVIO (inclisiran) injection, for subcutaneous use: US prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf. Accessed 24 Jan 2023.
Macchi C, Sirtori CR, Corsini A, et al. A new dawn for managing dyslipidemias: the era of RNA-based therapies. Pharmacol Res. 2019;150:104413.
Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–40.
Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067–75.
Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023. https://doi.org/10.1016/S2213-8587(22)00353-9.
European Medicines Agency. Leqvio (inclisiran) assessment report. 2020. https://www.ema.europa.eu. Accessed 24 Jan 2023.
Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77–89.
Kallend D, Stoekenbroek R, He Y, et al. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol. 2022;16(2):208–19.
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19.
Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–30.
Raal FJ, Kallend D, Ray KK, et al. Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia [abstract no. 018 / #1707]. Atherosclerosis. 2020;315:e7–8.
Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182–93.
Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2022;44(2):129–38.
Landmesser U, Haghikia A, Leiter LA, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021;117(1):284–91.
Ridker PM, Koenig W, Kastelein JJ, et al. Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention? Eur Heart J. 2018;39:4109–11.
Landmesser U, Conde LG, Wright RS, et al. Effect of inclisiran on haematological and immunological biomarkers: a pooled analysis of ORION-9, -10 and -11 trial data [abstract no. S025 / #1062]. Atherosclerosis. 2021;331:e37.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–37.
Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022. https://doi.org/10.1093/eurheartj/ehac615.
Brandts J, Ray KK. Clinical implications and outcomes of the ORION phase III trials. Future Cardiol. 2021;17(5):769–77.
Scicchitano P, Milo M, Mallamaci R, et al. Inclisiran in lipid management: a literature overview and future perspectives. Biomed Pharmacother. 2021;143:1–15.
Campbell C, Desai NR, Electricwala B, et al. The comparative efficacy of inclisiran, PCSK9 inhibiting monoclonal antibodies, and ezetimibe for the treatment of high cholesterol in adults with or at risk of ASCVD: a systematic literature review and network meta-analysis. J Am Coll Cardiol. 2022;79(9 Suppl. A):1551.
Burnett H, Fahrbach K, Cichewicz A, et al. Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Curr Med Res Opin. 2022;38(5):777–84.
Brandts J, Dharmayat KI, Vallejo-Vaz AJ, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021;325:46–56.
Merćep I, Friščić N, Strikić D, et al. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9—a narrative review. Cardiovasc Ther. 2022;2022:8129513.
Cupido AJ, Kastelein JJP. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. Cardiovasc Res. 2020;116(11):e136–9.
Azari S, Rezapour A, Omidi N, et al. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review. Heart Fail Rev. 2020;25:1077–88.
Lin G, Kazi D, Jih J, et al. Inclisiran and bempedoic acid for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value; evidence report: Institute for Clinical and Economic Review. Mar 2, 2021. http://icer.org/wp-content/uploads/2020/10/ICER_High-Cholesterol_Final-Evidence-Report_030221.pdf. Accessed 24 Jan 2023.
Campbell C, Desai NR, Electricwala B, et al. Cost-effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis [abstract]. J Am Coll Cardiol. 2022;79(9 Suppl. A):1559.
National Institute for Health and Clinical Care Excellence. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Technology appraisal guidance [TA733]. 2021. https://www.nice.org.uk/. Accessed 24 Jan 2023.
Acknowledgements
During the peer review process, the manufacturer of inclisiran was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
James E. Frampton is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
The manuscript was reviewed by: M. Rusica, Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy; P. Sabouret, Heart Institute, Cardiology Department, Pitié-Salpétrière, Sorbonne University and Collège National des Cardiologues Français Paris, France; P. Scicchitano, Cardiology Department, Hospital “F. Perinei”, Altamura, BA, Italy.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Frampton, J.E. Inclisiran: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs 23, 219–230 (2023). https://doi.org/10.1007/s40256-023-00568-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40256-023-00568-7